Welcome to our dedicated page for Fibrobiologics SEC filings (Ticker: FBLG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
FibroBiologics, Inc. filings document the regulatory record of a clinical-stage biotechnology issuer developing fibroblast-based therapies. Recent disclosures cover registered equity financing through an at-the-market common stock program, shelf registration mechanics, common stock and warrant-related capital structure matters, and corporate uses of proceeds for working capital and general corporate purposes.
The company’s SEC filings also record governance and public-company administration, including annual meeting proxy proposals, director election and auditor ratification matters, stock-plan option grants to executive officers, Nasdaq continued-listing compliance, amendments to stockholder-meeting quorum provisions, and material agreements affecting its operating footprint.
FibroBiologics, Inc. entered into agreements with institutional investors for a registered direct offering of 5,227,275 common shares at $0.33 each, raising approximately $1.7 million in gross proceeds before fees. In a concurrent private placement, the investors receive warrants to buy up to 5,227,275 additional shares at $0.33 per share, which become exercisable only if stockholders approve issuing the underlying shares.
If these investor warrants are later exercised for cash in full, the company would receive additional gross proceeds of about $1.7 million. H.C. Wainwright & Co. will receive cash fees equal to 7.0% of the purchase price plus a 1.0% management fee and warrants to buy up to 365,909 shares at $0.4125. The offerings are expected to close on or about December 16, 2025, and FibroBiologics plans to use the net proceeds for working capital and general corporate purposes.
FibroBiologics, Inc. is offering 5,227,275 shares of common stock at $0.33 per share in a registered direct offering to institutional investors, for gross proceeds of about $1.7 million and estimated net proceeds of roughly $1.5 million.
Each share is sold together with a warrant, in a concurrent unregistered private placement, to buy one additional share at $0.33, for up to 5,227,275 warrant shares. These warrants become exercisable only if stockholders approve the underlying share issuance and would expire five years after that approval.
The company plans to use the cash for working capital and general corporate purposes but states it will still need additional financing in the future to continue as a going concern. Recent November 2025 equity financings and the cash redemption of a $3.4 million convertible note have added new shares and warrants, while extensive outstanding derivative securities and current Nasdaq bid-price and market-value deficiency notices underscore dilution and listing-risk concerns.
FibroBiologics, Inc. insider activity shows that general counsel Ruben A. Garcia purchased 140,000 shares of common stock on December 11, 2025. The Form 4 reports this as a purchase coded “P” at a weighted average price of $0.34 per share, with individual trade prices ranging from $0.3333 to $0.3504. After these transactions, Garcia beneficially owns 140,000 shares of FibroBiologics common stock, held directly.
FibroBiologics, Inc. reported a financing transaction involving a registered direct offering and a concurrent private placement. The company agreed to sell 4,477,614 shares of common stock at $0.335 per share, for expected gross proceeds of about $1.5 million before fees. In the private placement, investors will also receive warrants to purchase up to 4,477,614 additional shares at an exercise price of $0.335 per share, which will become exercisable only if stockholders approve the issuance of the warrant shares.
If the investor warrants are later exercised for cash in full, FibroBiologics would receive about an additional $1.5 million. The company plans to use net proceeds from this financing for working capital and general corporate purposes. H.C. Wainwright & Co. will receive cash fees tied to the purchase price and non-accountable expenses, plus placement agent warrants to buy up to 313,433 shares at $0.4188 per share. The company agreed to a 30-day restriction on issuing additional equity and a one-year restriction on entering Variable Rate Transactions, subject to limited exceptions.
FibroBiologics, Inc. is registering 4,477,614 shares of common stock in a primary offering at $0.335 per share, raising gross proceeds of about $1.5 million and estimated net proceeds of approximately $1.2 million after fees. In a concurrent but separate private placement, investors also receive unregistered warrants on a one-for-one basis with a $0.335 exercise price, which become exercisable only if stockholders later approve the underlying warrant shares. The company plans to use the cash for working capital and general corporate purposes, but warns it will still need additional financing to continue as a going concern. New buyers face immediate dilution, and future exercises of options, warrants and convertible notes could further expand the share count. FibroBiologics also discloses Nasdaq notices for failing the $1.00 bid-price and $35 million market-value listing standards, creating a risk that its stock could be delisted if compliance is not regained.
FibroBiologics, Inc. is conducting a primary offering of 3,540,000 shares of common stock and pre-funded warrants to purchase up to 8,570,203 shares of common stock, together with the shares issuable upon exercise of those pre-funded warrants. The securities are sold to a single investor at $0.3303 per share (or $0.33029 per pre-funded warrant) and paired with privately placed warrants to purchase up to 12,110,203 additional shares, exercisable at $0.3303 per share if stockholders approve the related share issuance.
Payment for the common stock and pre-funded warrants will be made in 983 one-ounce sovereign-issued .9999 fine gold coins valued at $4,069.18 per ounce, which the company plans to liquidate into cash. Net proceeds are estimated at about $3.9 million and are expected to be used for general corporate purposes, including repayment of debt under a $15 million Standby Equity Purchase Agreement, where $3.4 million principal remained on the third note before redemption.
The company warns that it will still require additional financing to continue as a going concern and highlights potential dilution from derivative securities. It also discloses Nasdaq Capital Market listing deficiencies related to minimum bid price and market value of listed securities, noting that failure to regain compliance could lead to delisting and reduced liquidity for its common stock.
FibroBiologics, Inc. is conducting a primary offering of 3,540,000 shares of common stock and pre-funded warrants to purchase up to 8,570,203 shares of common stock, together with the shares issuable upon exercise of those pre-funded warrants. The securities are sold to a single investor at $0.3303 per share (or $0.33029 per pre-funded warrant) and paired with privately placed warrants to purchase up to 12,110,203 additional shares, exercisable at $0.3303 per share if stockholders approve the related share issuance.
Payment for the common stock and pre-funded warrants will be made in 983 one-ounce sovereign-issued .9999 fine gold coins valued at $4,069.18 per ounce, which the company plans to liquidate into cash. Net proceeds are estimated at about $3.9 million and are expected to be used for general corporate purposes, including repayment of debt under a $15 million Standby Equity Purchase Agreement, where $3.4 million principal remained on the third note before redemption.
The company warns that it will still require additional financing to continue as a going concern and highlights potential dilution from derivative securities. It also discloses Nasdaq Capital Market listing deficiencies related to minimum bid price and market value of listed securities, noting that failure to regain compliance could lead to delisting and reduced liquidity for its common stock.
FibroBiologics, Inc. (FBLG) entered into a securities purchase agreement with a single investor for a registered direct offering and concurrent private placement. The company will issue 3,540,000 shares of common stock and pre-funded warrants for up to 8,570,203 shares at prices of $0.3303 per share and $0.33029 per pre-funded warrant, plus unregistered warrants to purchase 12,110,203 shares at an exercise price of $0.3303, subject to stockholder approval. Payment will be made in sovereign-issued .9999 fine gold coins valued at $4,069.18 per ounce, which the company plans to quickly convert into cash, for expected gross proceeds of approximately $4.0 million, with the potential for about $4.0 million more if all unregistered warrants are exercised for cash. The company highlights valuation, operational, regulatory and tax risks tied to using physical gold as consideration. Separately, FibroBiologics exercised its right to redeem the remaining $3.4 million principal on a standby equity facility promissory note, expecting to pay $3,604,000 including a 6% redemption premium.
FibroBiologics, Inc. (FBLG) entered into a securities purchase agreement with a single investor for a registered direct offering and concurrent private placement. The company will issue 3,540,000 shares of common stock and pre-funded warrants for up to 8,570,203 shares at prices of $0.3303 per share and $0.33029 per pre-funded warrant, plus unregistered warrants to purchase 12,110,203 shares at an exercise price of $0.3303, subject to stockholder approval. Payment will be made in sovereign-issued .9999 fine gold coins valued at $4,069.18 per ounce, which the company plans to quickly convert into cash, for expected gross proceeds of approximately $4.0 million, with the potential for about $4.0 million more if all unregistered warrants are exercised for cash. The company highlights valuation, operational, regulatory and tax risks tied to using physical gold as consideration. Separately, FibroBiologics exercised its right to redeem the remaining $3.4 million principal on a standby equity facility promissory note, expecting to pay $3,604,000 including a 6% redemption premium.
FibroBiologics (FBLG) filed its Q3 2025 report showing higher expenses and a wider loss, alongside a going concern warning. For the quarter ended September 30, 2025, operating expenses rose to $5.0 million, driven by research and development of $2.8 million and general and administrative of $2.2 million. The company reported a net loss of $5.8 million for the quarter and $15.4 million for the nine months.
Cash and cash equivalents were $4.9 million, down from $14.0 million at year-end, with net cash used in operations of $13.2 million year-to-date. Management states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
The company detailed its Standby Equity Purchase Agreement, under which it issued $15.0 million in short-term convertible notes in three tranches and may require the investor to purchase up to an additional $10.0 million of common stock, subject to conditions. During 2025, $9.7 million of notes converted into 13,059,270 shares; additional conversions occurred in October. Shares outstanding were 48,263,979 as of September 30, 2025, and 51,456,077 as of October 31, 2025.
FibroBiologics, Inc. received a notification from the Nasdaq Listing Qualifications Staff that it does not meet the Nasdaq Capital Market requirement to maintain a minimum Market Value of Listed Securities (MVLS) of $35.0 million. The notice does not immediately affect the trading of the company’s common stock, but gives the company a 180-calendar-day cure period to regain compliance by having MVLS close at $35.0 million or more for at least ten consecutive business days before February 2, 2026. If the company fails to regain compliance, Nasdaq will notify FibroBiologics that its securities are subject to delisting, and the company may seek an appeal, though there is no assurance an appeal would be granted. The company stated it will monitor MVLS and consider options to regain compliance and filed this report to publicly disclose receipt of the Nasdaq notice.